Relapsed/Refractory HER2+ Metastatic Breast Cancer

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.

EP. 1: Best Practices: HER2+ MBC With Brain Mets

February 15th 2021

EP. 2: Frontline Standards of Care for HER2+ MBC

February 15th 2021

EP. 3: Case 1: 48-Year-Old Patient With HER2+ Metastatic Breast Cancer

February 23rd 2021

EP. 4: Treatment Strategies for Relapsed/Refractory HER2+ MBC

February 23rd 2021

EP. 5: Case 2: 61-Year-Old Patient With R/R HER2+ MBC

February 23rd 2021

EP. 6: Cancer Network Around the Practice: Relapsed/Refractory HER2+ Metastatic Breast Cancer

April 23rd 2021

This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.